CA3294499A1 - Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5-médicament, des anticorps anti-pd1/pd-l1 et des anticorps anti-ctla4 - Google Patents

Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5-médicament, des anticorps anti-pd1/pd-l1 et des anticorps anti-ctla4

Info

Publication number
CA3294499A1
CA3294499A1 CA3294499A CA3294499A CA3294499A1 CA 3294499 A1 CA3294499 A1 CA 3294499A1 CA 3294499 A CA3294499 A CA 3294499A CA 3294499 A CA3294499 A CA 3294499A CA 3294499 A1 CA3294499 A1 CA 3294499A1
Authority
CA
Canada
Prior art keywords
antibodies
drug conjugates
combinations containing
ceacam5 antibody
ctla4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3294499A
Other languages
English (en)
Inventor
Mustapha CHADJAA
Céline Nicolazzi
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of CA3294499A1 publication Critical patent/CA3294499A1/fr
Pending legal-status Critical Current

Links

CA3294499A 2023-06-05 2024-06-04 Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5-médicament, des anticorps anti-pd1/pd-l1 et des anticorps anti-ctla4 Pending CA3294499A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP23305883.3 2023-06-05

Publications (1)

Publication Number Publication Date
CA3294499A1 true CA3294499A1 (fr) 2024-12-12

Family

ID=

Similar Documents

Publication Publication Date Title
WO2021248048A8 (fr) Conjugués anticorps-médicament contenant un anticorps anti-mésothéline et leurs utilisations
MX2024015163A (es) Conjugado de anticuerpo anti-b7h3-farmaco y uso del mismo
SG11201901583WA (en) Anti-ctla4 and anti-pd-1 bifunctional antibody, pharmaceutical composition thereof and use thereof
ZA202204437B (en) Anti-pd-l1 antibodies and antibody-drug conjugates
EP4069297A4 (fr) Anticorps anti-avb6 et conjugués anticorps-médicament
EP4468808A3 (fr) Coexistence basée sur une priorité
EP4454662A4 (fr) Anticorps anti-dll3 et son utilisation pharmaceutique, et conjugué anticorps-médicament contenant un anticorps anti-dll3
NZ527173A (en) Specific human antibodies for selective cancer therapy
CA3242972A1 (fr) Anticorps anti-ror1, conjugue anticorps anti-ror1-medicament et leurs utilisations medicales
EP3930767A4 (fr) Conjugués d'anticorps-médicament comprenant des anticorps anti-tm4sf1 et leurs méthodes d'utilisation
IL312519A (en) Anticancer combinations containing antibody-drug conjugates anti-CEACAM5 and anti-VEGFR-2 antibodies
WO2023014809A9 (fr) Anticorps ciblant cd3 et leurs utilisations
MX2024013871A (es) Agentes aglutinantes 5t4 y usos de los mismos
CA3294499A1 (fr) Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5-médicament, des anticorps anti-pd1/pd-l1 et des anticorps anti-ctla4
MX2024013869A (es) Conjugados anticuerpo-farmaco 5t4 y usos de los mismos
MX2025014586A (es) Combinaciones antitumorales que contienen conjugados de anticuerpo anticeacam5-farmaco, anticuerpos anti-pd1/pd-l1 y anticuerpos anti-ctla4
WO2025117894A3 (fr) Immunoconjugués dimères destinés à être utilisés dans le traitement de cancers et procédés d'utilisation
EP4281189A4 (fr) Procédés de traitement du cancer utilisant des anticorps anti-tigit en combinaison avec des anticorps anti-pd1
CA3262971A1 (fr) Nouveaux anticorps anti-nectine-4 et conjugués anticorps-médicament
CA3284945A1 (fr) Combinaisons antitumorales contenant des conjugués anticorps-médicament anti-ceacam5, des anticorps anti-vegfr-2 et des anticorps anti-pd1/pd-l1
WO2006029220A3 (fr) Therapie combinee utilisant des anticorps anti-ctla4 et anti-4-1bb
IL319963A (en) Antibodies, antibody-drug conjugates, compositions and uses thereof
WO2024163920A3 (fr) Molécules de liaison anti-cd180 et leurs utilisations
HK40115494A (en) Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
HK40088234A (en) Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil